Home/Filings/4/0000899243-20-031172
4//SEC Filing

Sussman Joel F. 4

Accession 0000899243-20-031172

CIK 0001563577other

Filed

Nov 15, 7:00 PM ET

Accepted

Nov 16, 7:46 PM ET

Size

21.9 KB

Accession

0000899243-20-031172

Insider Transaction Report

Form 4
Period: 2020-11-12
Sussman Joel F.
Chief Accounting Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2020-11-12$1.07/sh+10,000$10,70010,000 total
  • Sale

    Common Stock

    2020-11-12$10.06/sh10,000$100,6270 total
  • Exercise/Conversion

    Common Stock

    2020-11-13$1.14/sh+3,755$4,2817,361 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-11-1210,0003,606 total
    Exercise: $1.07Exp: 2023-01-22Common Stock (10,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-11-133,6060 total
    Exercise: $1.07Exp: 2023-01-22Common Stock (3,606 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-11-132,63932,238 total
    Exercise: $2.43Exp: 2026-03-01Common Stock (2,639 underlying)
  • Exercise/Conversion

    Common Stock

    2020-11-13$1.07/sh+3,606$3,8583,606 total
  • Exercise/Conversion

    Common Stock

    2020-11-13$2.43/sh+2,639$6,41310,000 total
  • Sale

    Common Stock

    2020-11-13$10.32/sh10,000$103,1970 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-11-133,7550 total
    Exercise: $1.14Exp: 2024-09-16Common Stock (3,755 underlying)
Footnotes (3)
  • [F1]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The option has fully vested and is currently exercisable.

Issuer

Galera Therapeutics, Inc.

CIK 0001563577

Entity typeother

Related Parties

1
  • filerCIK 0001774297

Filing Metadata

Form type
4
Filed
Nov 15, 7:00 PM ET
Accepted
Nov 16, 7:46 PM ET
Size
21.9 KB